PepGen Inc. (PEPG)
| Bid | 2.7 |
| Market Cap | 88.6M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -90.23M |
| EPS (ttm) | -2.85 |
| PE Ratio (ttm) | -0.95 |
| Forward PE | -0.99 |
| Analyst | Buy |
| Ask | 2.71 |
| Volume | 1,344,495 |
| Avg. Volume (20D) | 2,891,837 |
| Open | 3.12 |
| Previous Close | 3.15 |
| Day's Range | 2.58 - 3.08 |
| 52-Week Range | 1.16 - 19.30 |
| Beta | 1.52 |
About PEPG
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1...
Analyst Forecast
According to 3 analyst ratings, the average rating for PEPG stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 342.80% from the latest price.
2 months ago · https://thefly.com
PepGen clinical hold likely to be resolved quickly, says LeerinkPepGen announced that the FDA has placed a clinical hold on the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in Duchenne muscular dystrophy, while the open-label Phase 2 CONNECT1-EDO51 study continues ex...